CA2557520A1 - A method for stabilizing blood pressure in hemodialysis subjects - Google Patents

A method for stabilizing blood pressure in hemodialysis subjects Download PDF

Info

Publication number
CA2557520A1
CA2557520A1 CA002557520A CA2557520A CA2557520A1 CA 2557520 A1 CA2557520 A1 CA 2557520A1 CA 002557520 A CA002557520 A CA 002557520A CA 2557520 A CA2557520 A CA 2557520A CA 2557520 A1 CA2557520 A1 CA 2557520A1
Authority
CA
Canada
Prior art keywords
receptor agonist
blood pressure
vasopressin
subject
hemodialysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002557520A
Other languages
French (fr)
Other versions
CA2557520C (en
Inventor
Donald W. Landry
Juan A. Oliver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2557520A1 publication Critical patent/CA2557520A1/en
Application granted granted Critical
Publication of CA2557520C publication Critical patent/CA2557520C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides

Abstract

The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.

Claims (13)

1. A method for reducing excess extracellular fluid in a subject undergoing hemodialysis comprising administering a V-1 receptor agonist to the subject in an effective amount and thereby maintaining blood pressure during hemodialysis in order to facilitate reducing excess extracellular fluid in the subject.
2. A method for stabilizing high blood pressure between hemodialysis treatments in a subject undergoing hemodialysis by reducing excess extracellular fluid by the method of claim 1.
3. A method for inhibiting interdialytic hypertension by regulating blood pressure by the method of claim 2.
4. A method for inhibiting intradialytic hypotension by regulating blood pressure by the method of claim 1.
5. The method of claim 1, wherein the V-1 receptor agonist is arginine vasopressin.
6. The method of claim 1, wherein the V-1 receptor agonist is lysine vasopressin.
7. The method of claim 1, wherein the V-1 receptor agonist is terlipressin.
8. The method of claim 1, wherein the V-1 receptor agonist is octapressin
9. The method of claim 1, wherein the V-1 receptor agonist is ornipressin
10. The method of claim 1, wherein the V-1 receptor agonist is an organic molecule selected from the group consisting of 3-beta-(2-thienyl)-L-alanine)-8-lysine-vasopressin, N-alpha-glycyl-glycyl-glycyl-[8-lysine]-vasopressin, and 1-deamino-6-carba-[8-arginine]-vasopressin.
11. The method of claim 1, wherein the effective amount of the V-1 receptor agonist is in a range of about 0.05 milliunits/kg/minute - 2.0 milliunits/kg/hr.
12. The method of claim 1, wherein the effective amount of the V-1 receptor agonist is about 0.3 milliunits/kg/minute.
13. The method of claim 1, wherein the subject is a human, non-human primate, rabbit, sheep, rat, dog, cat, pig, or mouse.
CA2557520A 2003-02-26 2004-02-26 A method for stabilizing blood pressure in hemodialysis subjects Expired - Lifetime CA2557520C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45060903P 2003-02-26 2003-02-26
US60/450,609 2003-02-26
PCT/US2004/006029 WO2004075783A2 (en) 2003-02-26 2004-02-26 A method for stabilizing blood pressure in hemodialysis subjects

Publications (2)

Publication Number Publication Date
CA2557520A1 true CA2557520A1 (en) 2004-09-10
CA2557520C CA2557520C (en) 2011-09-13

Family

ID=32927674

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2557520A Expired - Lifetime CA2557520C (en) 2003-02-26 2004-02-26 A method for stabilizing blood pressure in hemodialysis subjects

Country Status (3)

Country Link
US (2) US7183255B2 (en)
CA (1) CA2557520C (en)
WO (1) WO2004075783A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075783A2 (en) * 2003-02-26 2004-09-10 Landry Donald W A method for stabilizing blood pressure in hemodialysis subjects
JO2937B1 (en) 2004-08-11 2016-03-15 فيرينغ.بي.في Peptidic Vasopressin Receptor Agonists
NZ569836A (en) * 2006-02-10 2010-09-30 Ferring Bv Novel compounds
US8222202B2 (en) * 2006-02-13 2012-07-17 Ferring B.V. Use of peptidic vasopressin receptor agonists
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
WO2009045309A2 (en) * 2007-09-28 2009-04-09 Ferring B.V. Use of v2 receptor antagonists in combination with vasopressinergic agonists
US7879069B2 (en) * 2007-10-26 2011-02-01 Global Monitors, Inc. Anti-pooling vest for patients undergoing hemodialysis and in critical care
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
US9177129B2 (en) * 2012-06-27 2015-11-03 Intel Corporation Devices, systems, and methods for monitoring and asserting trust level using persistent trust log

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457055B (en) * 1986-08-18 1988-11-28 Ferring Ab TOPIC RADIATION GEL FOR MUKOSA CONTAINING VARIETY CONDUCTIVE SUBSTANCES
JPH09507867A (en) 1994-11-17 1997-08-12 バクスター、インターナショナル、インコーポレイテッド Hemoglobin therapy in hemodialysis
WO2004075783A2 (en) * 2003-02-26 2004-09-10 Landry Donald W A method for stabilizing blood pressure in hemodialysis subjects

Also Published As

Publication number Publication date
CA2557520C (en) 2011-09-13
US7183255B2 (en) 2007-02-27
WO2004075783A2 (en) 2004-09-10
US20040229798A1 (en) 2004-11-18
US20070213259A1 (en) 2007-09-13
WO2004075783A3 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
Matsumura et al. Angiotensin II acts at AT1receptors in the nucleus of the solitary tract to attenuate the baroreceptor reflex
Machado et al. Mechanisms of angiotensin-(1–7)-induced inhibition of angiogenesis
Cesari et al. Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases
CA2557520A1 (en) A method for stabilizing blood pressure in hemodialysis subjects
ATE390142T1 (en) SYNERGISTIC COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS
ATE462427T1 (en) USE OF TREPROSTINIL TO TREAT NEUROPATHIC DIABETIC FOOT ULCERS
MX2009004424A (en) Neuronal exocytosis inhibiting peptides.
DK0738262T3 (en) New Heterocyclic Compounds
RU2661109C2 (en) Angiotensin in treating brain conditions
BR0310047A (en) 8-azaprostaglandin analogues as agents for intraocular pressure decrease
Wright et al. Aminopeptidase-induced elevations and reductions in blood pressure in the spontaneously hypertensive rat
Sharma et al. Nitric oxide inhibits the expression of AT1 receptors in neurons
WO2003093313A3 (en) Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
NZ610732A (en) Novel angiotensin type 2 (at2) receptor agonists and uses thereof
DD158238A5 (en) METHOD FOR PRODUCING A NEW INHIBITOR FOR ANGIOTENSE CONVERTING ENZYME
DE602004002394D1 (en) (3-ä3 - '(2,4-BIS-TRIFLUOROMETHYL-BENZYL) - (5-ETHYL-PYRIMIDIN-2-YL) -AMINOÜ-PROPOXYU-PHENYL) ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHOD FOR THE TREATMENT OF METABOLIC DISORDERS
DE60219614D1 (en) 3, 7 THIAPROSTANSÄUREDERIVATE AS A MEANS FOR THE REDUCTION OF THE AUGENINNENDRUCKES
ATE360424T1 (en) 2,3,4,5-TETRAHYDROBENZO[FÖ]1,4ÖOXAZEPINE-5-CARBONIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S
KR20160016872A (en) Angiotensin peptides in treating marfan syndrome and related disorders
Abramov et al. Regulation of feeding by galnon
Nakamura et al. Cardiovascular responses to microinjections of urocortin 3 into the nucleus tractus solitarius of the rat
IL117816A0 (en) N-subsituted azaheterocyclic compounds their preparation and pharmaceutical compositions containing them
Pandey et al. Protective effects of aprotinin on respiratory and cardiac abnormalities induced by Mesobuthus tamulus venom in adult rats
Wright et al. Use of aminopeptidase M as a hypotensive agent in spontaneously hypertensive rats
CN1322212A (en) Neuropeptide Y agaonists

Legal Events

Date Code Title Description
EEER Examination request